Table 1.
Clinical and demographic variables of participants and non-participants
| Participants N=440 | Non-participantsa N= 1207 | P-value | |
|---|---|---|---|
| Mean age at cancer diagnosis (SD) | 42.10 (6.09) | 42.61 (6.37) | 0.15 |
| Stage (n (%)) | |||
| Localized | 230 (52.3) | 580 (48.1) | 0.08 |
| Regional | 182 (41.4) | 502 (41.6) | |
| Distant | 21 (4.8) | 95 (7.9) | |
| Unstaged | 7 (1.6) | 30 (2.5) | |
| Histologic subtype (n (%)) | |||
| Ductal | 347 (78.9) | 976 (80.9) | 0.47 |
| Lobular | 25 (5.7) | 48 (4.0) | |
| Mixed | 29 (6.6) | 84 (7.0) | |
| Other/Unknown | 39 (8.9) | 99 (8.2) | |
| ER/PR/HER2 receptor status known (n (%)) | 291 (66.1) | 776 (64.3) | 0.49 |
| Receptor status (n (%))b | |||
| Triple negative | 78 (26.8) | 188 (24.2) | 0.39 |
| Non-triple negative | 213 (73.2) | 588 (75.8) | |
| Married or cohabiting (n (%)) | |||
| Yes | 173 (39.3) | 524 (43.4) | 0.26 |
| no | 260 (59.1) | 659 (54.6) | |
| Unknown | 7 (1.6) | 24 (2.0) | |
| Insurance at diagnosis (n (%)) | |||
| Not Insured | 47 (10.7) | 114 (9.4) | 0.79 |
| Private Insurance | 245 (55.7) | 709 (58.7) | |
| Medicaid | 73 (16.6) | 192 (15.9) | |
| Medicare | 21 (4.8) | 45 (3.7) | |
| Military or Indian public health services | 16 (3.6) | 34 (2.8) | |
| Other Insurance | 33 (7.5) | 94 (7.8) | |
| Unknown | 5 (1.1) | 19 (1.6) | |
| Employment at diagnosis (n (%)) | |||
| Unemployed | 51 (11.6) | 133 (11.0) | 0.62 |
| Employed | 275 (62.5) | 732 (60.6) | |
| Unknown | 114 (25.9) | 342 (28.3) | |
| Metropolitan (n (%)) | 422 (95.9) | 1159 (96.5) | 0.92 |
access to genetic services
a
There were 16 individuals included with “non-participants” who consented but did not complete the baseline survey.
b
Valid percentages are shown based on those individuals where information for all three receptors was known.